Nonetheless, the CAPTURE study demonstrated that patients with previous cardiovascular disease were slightly less likely to be prescribed GLP-1 RA than patients without previous cardiovascular disease (9.5% versus 10.4%) [6]. Here, GLP1R is linked to cardiovascular disorder.